Literature DB >> 14560993

Human colon carcinomas constitutively express and shed type II IL-1 receptor, an IL-1 antagonist.

Andrew W Stadnyk1, Moorix M W Yeung, Sen Rong Yan.   

Abstract

We reported earlier that rat intestinal epithelial cells respond to helminth infection, to NSAID injury, and to detachment in vitro with expression of the IL-1RII. Now we have sought to determine whether human colon carcinoma cell lines express, or may be induced to express, this potent IL-1 antagonist. Using RT-PCR, the T84 and HT-29 cell lines constitutively expressed mRNA for the membrane-bound, but not the secreted variant of the receptor. The protein was detectable by immunohistochemistry and was estimated to be 70 kDa by western blotting. TNF treatment of T84 cells led to slightly increased levels of IL-1RII mRNA and to significant increases in soluble protein detected in culture supernatants. Treating T84 cells with inhibitory anti-IL-1RII antibodies led to heightened responsiveness to IL-1, measured as IL-8 production. Expression of the IL-1RII by human epithelial cells has implications in terms of the IL-1 agonist versus antagonist balance in the diseased intestines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560993     DOI: 10.1023/a:1025490911140

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  50 in total

1.  Rapid expression of IL-1beta by intestinal epithelial cells in vitro.

Authors:  C C Waterhouse; A W Stadnyk
Journal:  Cell Immunol       Date:  1999-04-10       Impact factor: 4.868

2.  Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.

Authors:  E Vannier; A Kaser; M B Atkins; G Fantuzzi; C A Dinarello; J W Mier; H Tilg
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

3.  The membrane form of the type II IL-1 receptor accounts for inhibitory function.

Authors:  D Neumann; C Kollewe; M U Martin; D Boraschi
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

4.  Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA.

Authors:  C Liu; R P Hart; X J Liu; W Clevenger; R A Maki; E B De Souza
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

5.  Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.

Authors:  F Cominelli; C C Nast; B D Clark; R Schindler; R Lierena; V E Eysselein; R C Thompson; C A Dinarello
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Neutrophil migration stimulates rat intestinal epithelial cell cytokine expression during helminth infection.

Authors:  A W Stadnyk; C D Dollard; A C Issekutz
Journal:  J Leukoc Biol       Date:  2000-12       Impact factor: 4.962

7.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4.

Authors:  F Colotta; F Re; M Muzio; R Bertini; N Polentarutti; M Sironi; J G Giri; S K Dower; J E Sims; A Mantovani
Journal:  Science       Date:  1993-07-23       Impact factor: 47.728

9.  Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD).

Authors:  S Dionne; I D D'Agata; J Hiscott; T Vanounou; E G Seidman
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

10.  Increased concentrations of interleukin 1 beta, interleukin-2, and soluble interleukin-2 receptors in endoscopical mucosal biopsy specimens with active inflammatory bowel disease.

Authors:  J Brynskov; N Tvede; C B Andersen; M Vilien
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

View more
  1 in total

1.  Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells.

Authors:  Xiwei Liu; Li Min; Hong Duan; Rui Shi; Wenli Zhang; Song Hong; Chongqi Tu
Journal:  Med Oncol       Date:  2014-11-29       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.